441 - There is a unique provincial situation in which the manufacturer has lowered the price of its drug to match the price of its generic substitute. Can we create an APS that speaks to this fact and claim that patients can continue to receive said drug "at no additional cost* compared to the generic version."? *Refers to the drug acquisition cost; dispensing fees not covered.

  • A Q&A forum is not the optimal forum for this type of question as it requires a review. I will not speak to your particular case (as I don’t know the details). I will say that a message such as “at no additional cost” suggests that no patient ever needs to pay more than they would for the generic alternative. This claim is misleading unless it is unequivocally true.

Log in to reply